Non-target screening using chromatography coupled to high-resolution mass spectrometry is a powerful tool in environmental ...
BioAtla has engaged Tungsten Advisors as the Company’s exclusive strategic financial advisor. There can be no assurance that this process will result in any such transaction. BioAtla does not intend ...
2don MSNOpinion
Opinion: New strategy, same watchdog: Congress still has a role to play in PEPFAR’s transition
Congress must ensure that the transition of PEPFAR to full partner country ownership is data-driven, includes input from ...
Monoclonal antibodies have become one of the most established and clinically successful therapeutic modalities, supported by ...
Heineken sticks to EverGreen 2030 amid CEO change, detailing cost cuts, digital/AI, capital discipline and growth markets as ...
Calgary Herald on MSN
Council approves six focuses for next budget cycle, but some criticize the process
Calgary city council on Tuesday approved a blueprint to establish six focus areas for the next four-year budget cycle — ...
2d
Inovio targets October 30 PDUFA date for INO-3107 approval while extending cash runway into Q4 2026
CEO Jacqueline Shea highlighted that "these are very exciting times for Inovio with our first BLA for INO-3107 as a potential treatment for adults with recurrent respiratory papillomatosis or RRP, ...
March 13, 2026 - PRESSADVANTAGE - Infintech Designs published a detailed blog addressing the strategy, methodology, and ...
Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing markets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results